Chemotherapy: Open Access
Open Access

Martin L

Publications

• Research Article
  RXDX-107, A Dodecanol Alkyl Ester of Bendamustine, Demonstrates Greater Stability and Broad Antitumor Activity in Multiple Pre-Clinical Models of Solid Tumor
  Author(s): Martin L, Johnson M, Patel R, Walsh C, Chua P, Tindall E, Shoemaker R, Oliver J, Lin R and Li G Martin L, Johnson M, Patel R, Walsh C, Chua P, Tindall E, Shoemaker R, Oliver J, Lin R and Li G
  
  Purpose: RXDX-107 is a dodecanol alkyl ester of bendamustine encapsulated in human serum albumin (HSA) to form nanoparticles. The anti-tumor activity of bendamustine in solid tumor malignancies has been less impressive, partially due to short half-life. RXDX-107 was designed to extend the half-life and improve tissue biodistribution over bendamustine, which may result in superior efficacy and tolerability in patients with solid tumors. Experimental Design: The anti-tumor activity of RXDX-107 was measured in cellular anti-proliferation assay, cell-line derived xenograft (CDX) models and patient-derived xenograft (PDX) models. The mechanism of action and pharmacodynamics properties were measured by comet assay. The tumor accumulation was measured by a novel LC-MS/MS method. Results: .. View More»
  DOI: 10.4172/2167-7700.1000213

  Abstract PDF

Relevant Topics